These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8748047)

  • 1. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder.
    Mandos LA; Rickels K; Cutler N; Roeschen J; Keppel Hesselink JM; Schweizer E
    Int Clin Psychopharmacol; 1995 Nov; 10(4):251-6. PubMed ID: 8748047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
    J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
    Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
    Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
    J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.
    Kasper S; Iglesias-García C; Schweizer E; Wilson J; DuBrava S; Prieto R; Pitman VW; Knapp L
    Int J Neuropsychopharmacol; 2014 May; 17(5):685-95. PubMed ID: 24351233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
    Lemoine P; Rouillon F; Pouget D
    Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clorazepate and lorazepam: clinical improvement and rebound anxiety.
    Rickels K; Fox IL; Greenblatt DJ; Sandler KR; Schless A
    Am J Psychiatry; 1988 Mar; 145(3):312-7. PubMed ID: 2894175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
    Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
    Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
    Fresquet A; Sust M; Lloret A; Murphy MF; Carter FJ; Campbell GM; Marion-Landais G
    Ann Pharmacother; 2000 Feb; 34(2):147-53. PubMed ID: 10676820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
    Delle Chiaie R; Pancheri P; Casacchia M; Stratta P; Kotzalidis GD; Zibellini M
    J Clin Psychopharmacol; 1995 Feb; 15(1):12-9. PubMed ID: 7714222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.
    Bourin M; Malinge M
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):567-75. PubMed ID: 8588056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation.
    Romach MK; Kaplan HL; Busto UE; Somer G; Sellers EM
    J Clin Psychopharmacol; 1998 Apr; 18(2):121-31. PubMed ID: 9555597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of withdrawal of buspirone and diazepam: a placebo controlled study.
    Fontaine R; Beaudry P; Beauclair L; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):189-97. PubMed ID: 2888159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
    Feltner DE; Harness J; Brock J; Sambunaris A; Cappelleri JC; Morlock R
    CNS Neurosci Ther; 2009; 15(1):12-8. PubMed ID: 19228175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a putative anxiolytic agent: ipsapirone.
    Borison RL; Albrecht JW; Diamond BI
    Psychopharmacol Bull; 1990; 26(2):207-10. PubMed ID: 1978371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder.
    Cohn JB; Wilcox CS
    Pharmacotherapy; 1984; 4(2):93-8. PubMed ID: 6144090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
    Cohn JB; Wilcox CS
    J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
    Laakmann G; Schüle C; Lorkowski G; Baghai T; Kuhn K; Ehrentraut S
    Psychopharmacology (Berl); 1998 Apr; 136(4):357-66. PubMed ID: 9600581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial.
    Herrera-Arellano A; Jiménez-Ferrer JE; Zamilpa A; García-Alonso G; Herrera-Alvarez S; Tortoriello J
    Planta Med; 2012 Sep; 78(14):1529-35. PubMed ID: 22828921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.